Diaceutics PLC (LON:DXRX - Get Free Report) insider Nick Roberts purchased 91 shares of the business's stock in a transaction dated Wednesday, October 1st. The shares were acquired at an average cost of GBX 165 per share, for a total transaction of £150.15.
Diaceutics Stock Performance
Diaceutics stock opened at GBX 165 on Thursday. The firm has a market capitalization of £139.50 million, a price-to-earnings ratio of -8,168.32 and a beta of 0.58. Diaceutics PLC has a 52 week low of GBX 106 and a 52 week high of GBX 167. The company has a debt-to-equity ratio of 0.39, a quick ratio of 9.92 and a current ratio of 4.85. The company has a 50 day moving average price of GBX 142.58 and a 200 day moving average price of GBX 129.32.
Diaceutics (LON:DXRX - Get Free Report) last announced its earnings results on Tuesday, September 23rd. The company reported GBX (2.84) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. Research analysts forecast that Diaceutics PLC will post 1.0107919 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. Royal Bank Of Canada decreased their price objective on Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating for the company in a report on Thursday, July 10th. Canaccord Genuity Group restated a "buy" rating and issued a GBX 180 price target on shares of Diaceutics in a research note on Tuesday, July 22nd. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of GBX 175.
Check Out Our Latest Research Report on DXRX
About Diaceutics
(
Get Free Report)
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diaceutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.
While Diaceutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
